Palvella Therapeutics is a late-clinical-stage biopharmaceutical company built entirely around its patented QTORIN™ anhydrous gel delivery platform, which solves the decades-old problem of delivering high concentrations of rapamycin (and related mTOR inhibitors) deep into the skin while keeping systemic exposure essentially zero. Every single asset in the pipeline leverages this same core technology, creating one of the strongest platform moats in rare-disease biotech.The lead program, QTORIN™ 3.9% rapamycin for pachyonychia congenita (PC), targets a devastating keratin gene disorder affecting 6,000–10,000 patients in the U.S. PC patients suffer excruciating plantar calluses that make walking feel like stepping on nails, along with nail dystrophy, follicular hyperkeratosis, and oral leukokeratosis from birth.